$NBIX

AI Analysis

Generated on May 11, 2026

AI Score
74/ 100
Hold$NBIX

Neurocrine Biosciences

$NBIXNASDAQHealthcareLarge-Cap

Neurocrine develops treatments for neurological and endocrine disorders including Ingrezza for tardive dyskinesia.

Market Cap
$14.0B
Revenue (TTM)
$2.2B
+18.0%
Net Income (TTM)
$0.5B
+25.0%
EPS (TTM)
$3.60
P/E Ratio
38.0
Dividend Yield
0.0%
52-Week Range
$105-$155
Beta
0.42
Dimension Scores
Fundamental
72
Technical
70
Sentiment
76
Risk / Reward
72
Momentum
74
FundTechSentRiskMome
Financial Health
Profitability
77strong
Growth
77strong
Liquidity
80strong
Solvency
74strong
Efficiency
70strong

Valuation, technical analysis, investment thesis, risk assessment and more for $NBIX

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.